批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/06/10 |
SUPPL-52(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/09/24 |
SUPPL-50(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/03/27 |
SUPPL-48(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/04/14 |
SUPPL-47(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/01/27 |
SUPPL-44(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/11/09 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/09 |
SUPPL-39(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/05/06 |
SUPPL-38(补充) |
Approval |
REMS |
N/A
|
|
|
2011/03/25 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/01/07 |
SUPPL-36(补充) |
Approval |
REMS |
N/A
|
|
|
2010/07/20 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/01/13 |
SUPPL-32(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/06/24 |
SUPPL-27(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2007/08/16 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/04/13 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/02/24 |
SUPPL-25(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/05/24 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/12/22 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/07/29 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/31 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/18 |
SUPPL-19(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2002/03/27 |
SUPPL-17(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2001/02/23 |
SUPPL-15(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2000/11/06 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2000/08/10 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/10/25 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/08/05 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1999/06/01 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1998/09/11 |
SUPPL-9(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1998/05/20 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1998/05/20 |
SUPPL-2(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1998/01/16 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1997/11/21 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1997/09/24 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1997/09/19 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1996/06/21 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:NEVIRAPINE 剂型/给药途径:TABLET;ORAL 规格:200MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020636 |
001 |
NDA |
VIRAMUNE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Discontinued |
Yes |
No |
AB |
1996/06/21
|
BOEHRINGER INGELHEIM |
077521 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
AUROBINDO |
077956 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
CIPLA |
078195 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
STRIDES PHARMA |
078584 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
HETERO LABS LTD III |
078644 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Discontinued |
No |
No |
AB |
2012/05/22
|
PRINSTON INC |
202523 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
MYLAN PHARMS INC |
203080 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
No |
AB |
2012/05/22
|
MICRO LABS LTD |
090688 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
TABLET;ORAL |
200MG |
Prescription |
No |
Yes |
AB |
2019/01/14
|
MACLEODS PHARMS LTD |